glp-1 non-diabetic weight loss effectiveness Agonists For Obesity In Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Only a few week old

2007;72:R138R151

Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes

Retracted article: Melatonin protects spinal cord injury by up-regulating IGFBP3 through the improvement of microcirculation in a rat model

GLP-1 receptor agonists reduced dopamine release following stimulatory effects produced by alcohol, cocaine, nicotine, and amphetamines in animal studies

This article explores the current status of oral GLP-1 drugs, what they mean for diabetes care, and how they may change the treatment landscape

The drugs have shown positive effects on liver function tests and possible advantages in non-alcoholic fatty liver disease (Liao et al